Press Room

DCAT Week 2023

Start
Monday, March 20, 2023 - 09:00
End
Thursday, March 23, 2023 - 18:00
Location: New York, United States

Meet us at theDCAT Weekand schedule a meeting nowwith our key experts at The Lexington Hotel.

Schedule a meeting button | ɫAV

Learn how ɫAV can support your projects and the production of your much needed medicines and breakthrough therapies.

You might be interested in:

Continuous Tableting for your drug product. The future is continuous | ɫAV
Continuous tableting is suited for all types of drug products for oral delivery, and allows for leaner and risk-reduced development paths, leaner supply chains, increased built-in quality, and more flexible and less complex manufacturing processes. Meet our team and find out why The future is continuous.

Dispersome® Learn more about the innovative technology capable of solving the poor solubility issues of your drug candidate | ɫAV

Dispersome® technology enables the formulation of API with a novel protein-based excipient, developing ASDs with high solubility and bioavailability which can be manufactured at a large-scale using Spray Drying. If you are developing a novel drug formulation or need to improve your drug candidate, .

Let’s discuss your project together.

Also in the Press Room

See All

Lisbon, Portugal – ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ɫAV’s sustainability ambitions.  ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024